Abstract
Systemic vasculitides are heterogeneous disabling diseases characterised by chronic inflammation of the blood vessels potentially leading to tissue destruction and organ failure. The recent COVID-19 pandemic has had a significant impact on the epidemiology and management of patients with systemic vasculitis. In parallel, new insights have been provided on systemic vasculitis pathogenetic mechanisms, possible new therapeutic targets, and newer glucocorticoid-sparing treatments with better safety profiles. As in the previous annual reviews of this series, in this review we will provide a critical digest of the most recent literature regarding pathophysiology, clinical manifestations, diagnostic tools and treatment options in small- and large-vessel vasculitis focusing on precision medicine in vasculitis.
Author supplied keywords
Cite
CITATION STYLE
Moretti, M., Treppo, E., Monti, S., La Rocca, G., Del Frate, G., Delvino, P., … Baldini, C. (2023, April 1). Systemic vasculitis: one year in review 2023. Clinical and Experimental Rheumatology. Clinical and Experimental Rheumatology S.A.S. https://doi.org/10.55563/clinexprheumatol/zf4daj
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.